ClinicalTrials.gg
RecruitingNCT07104487Updated Aug 11, 2025

[18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease

A Phase 2 interventional study of [18F]AlF-OC in Stroke (CVA) or TIA, Carotid Artery Plaque and Atherosclerosis Cardiovascular Disease, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Mar 2025, registered Jul 2025).
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven — 4 open to participants now, 4 under way, none of them phase 3. Stroke · Universitaire Ziekenhuizen KU Leuven.

Started
2025
with 1 other
Phase 2
Only one
of the 11
Registered
11th of 11
by date

Among the 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven, this one is one of 2 that started in 2025, is the only one in phase 2, and was the 11th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

4 of the 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven, or all of them as a file.
02

Study summary

This clinical trial aims to evaluate whether [¹⁸F]AlF-OC PET/MRI can characterize and quantify inflammation in carotid atherosclerotic plaques. The study will assess if tracer uptake in culprit and non-culprit carotid arteries, measured by standardized uptake values (SUV), is associated with future cerebrovascular events. Specifically, it will examine whether [¹⁸F]AlF-OC uptake predicts the risk of recurrent ipsilateral TIA, amaurosis fugax, stroke, or other vascular complications.

Participants will undergo [¹⁸F]AlF-OC PET/MRI and will be followed via telephone interviews at 90 days, 1 year, and 3 years after their initial stroke or TIA.

Read the detailed description

Our study aims to assess the potential of molecular imaging with [18F]AlF-OC PET/MRI to characterize and quantify carotid atherosclerotic disease manifestations in patients with a recent stroke/TIA in the carotid artery territory. Eligible patients should have ≥30% stenosis in the ipsilateral carotid artery, as diagnosed by routine CTA. Additionally, we will evaluate the role of [18F]AlF-OC PET/MRI in risk stratification for recurrent events of patients with carotid artery stenosis and recent TIA/stroke.

This study is a single center study conducted at University Hospitals Leuven in Belgium. In a first part of this study, five patients will undergo serial [18F]AlF-OC PET/MRI at 60, 120 and 180 minutes after injection of 4 MBq/kg [18F]AlF-OC for protocol optimization and methodology refinement. In the second part of this trial, patients will undergo [18F]AlF-OC PET/MRI at the timepoint deemed as optimal based on the findings from the first part. All subjects will be required to undergo a screening and baseline assessment, an imaging visit ([18F]AlF-OC PET/MRI) and three follow-up visits (telephone interview at 90 days, 1 year and 3 years after the initial stroke onset). The primary outcome is the quantification of [18F]AlF-OC uptake in the carotid artery by measures of standardized uptake value (SUV). For every patient, both culprit (recent symptomatic event in ipsilateral carotid artery territory) and non-culprit (recent symptomatic event in the contralateral carotid artery territory) carotid arteries will be assessed. Secondary outcomes include the predictive value of baseline plaque SUV and TBR for the recurrence of ipsilateral TIA, amaurosis fugax and stroke during 3 years follow-up, the recurrence of all stroke/TIA, the occurrence of any vascular complication (stroke/TIA, myocardial infarction, cardiac arrest, hospitalisation for unstable angina or vascular death) and the occurrence of all-cause mortality.

03

Conditions studied

  • Stroke (CVA) or TIA
  • Carotid Artery Plaque
  • Atherosclerosis Cardiovascular Disease
  • Carotid Arteriosclerosis

Keywords

  • Internal Carotid Artery
  • Molecular Imaging
  • Atherosclerosis
  • Inflammation
  • PET/MRI
  • SST2
  • [18F]AlF-NOTA-octreotide
  • Stroke/TIA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is aged over 18 years.
  2. Voluntary written of the participant or their legally authorized representative has been obtained prior to any screening procedure
  3. CT angiography imaging at baseline should be available as part of routine care
  4. Participant is diagnosed with a recent ischemic stroke or high-risk (ABCD2 ≥ 4) in the carotid artery territory and ≥ 30% carotid artery stenosis. The stroke/TIA has occurred no more than 21 days prior to tracer administration.

Exclusion criteria

Exclusion Criteria:

  1. Female who is pregnant or breast-feeding
  2. Participants with a cardio-embolic stroke, small vessel stroke or other defined stroke etiology according to the TOAST classification (23)
  3. Participant has a previous or ongoing recurrent or chronic disease at high risk to interfere with the performance or evaluation of the trial, according to the judgment of the investigator
  4. Participants treated with carotid endarterectomy or carotid artery stenting within the past year
  5. Subject has a for or cannot tolerate MR scanning
  6. Subject has an impaired renal function estimated (eGFR) \< 40 ml/min/1.73m² (the last known value may not date from more than 3 months prior to the study PET/MR; if not available a blood analysis may be performed as part of the trial)
  7. Concurrent treatment with and/or somatostatin analogues
  8. Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Part A

    5 patients with ≥30% carotid artery stenosis on routine CT angiography (CTA) and a recent ischemic stroke in the supplying carotid artery territory will undergo \[18F\]AlF-OC PET/MRI at 60, 120 and 180 minutes after tracer injection.

    Drug: [18F]AlF-OC

  • Experimental
    Arm B

    19 patients with ≥30% carotid artery stenosis on routine CTA and a recent ischemic stroke/TIA in the supplying carotid artery territory will undergo \[18F\]AlF-OC PET/MRI at the timepoint deemed optimal in part A of the study.

    Drug: [18F]AlF-OC

Interventions

  • Drug[18F]AlF-OC

    Participants received a single intravenous (IV) bolus injection of 4 MBq/kg \[¹⁸F\]AlF-OC (Al¹⁸F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide), followed by a flush with 0.9% NaCl.

06

What researchers measure

Primary outcomes

  1. Quantification of ICA [18F]AlF-OC uptake

    Quantification of \[18F\]AlF-OC uptake in the culprit and non-culprit carotid artery by measures of standardized uptake value (SUV)

    Time frame: 1 hour post-injection

Secondary outcomes

  1. Recurrence of ipsilaterial TIA, stroke or amaurosis fugax

    Recurrence of ipsilateral TIA, amaurosis fugax and stroke during follow-up

    Time frame: 90 days, 1 year and 3 years after index event

  2. Recurrence of all stroke/TIA

    Recurrence of all stroke/TIA during follow-up

    Time frame: 90 days, 1 year and 3 years after the index event

  3. Occurence of major adverse cardiovascular events (MACE)

    Occurence of any vascular complication (stroke/TIA, myocardial infarction, cardiac arrest, hospitalisation for unstable angina or vascular death) during follow-up

    Time frame: 90 days, 1 year and 3 years after index event

  4. Occurence of all-cause mortality

    Occurence of all-cause mortality during follow-up

    Time frame: 90 days, 1 year, 3 years after index event

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Boeckxstaens L, Pauwels E, Vandecaveye V, Deckers W, Cleeren F, Dekervel J, Vandamme T, Serdons K, Koole M, Bormans G, Laenen A, Clement PM, Geboes K, Van Cutsem E, Nackaerts K, Stroobants S, Verslype C, Van Laere K, Deroose CM. Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients. EJNMMI Res. 2023 Jun 1;13(1):53. doi: 10.1186/s13550-023-01003-3. PubMed 37261615 ↗
  • Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, Van Cutsem E, Verslype C, Van Laere K, Bormans G, Deroose CM. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3033-3046. doi: 10.1007/s00259-020-04918-4. Epub 2020 Jul 2. PubMed 32617641 ↗
  • Maes L, Versweyveld L, Evans NR, McCabe JJ, Kelly P, Van Laere K, Lemmens R. Novel Targets for Molecular Imaging of Inflammatory Processes of Carotid Atherosclerosis: A Systematic Review. Semin Nucl Med. 2024 Sep;54(5):658-673. doi: 10.1053/j.semnuclmed.2023.10.004. Epub 2023 Nov 23. PubMed 37996309 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Sep 2026, 18 months after the start.

Of 112 non-industry phase 2 interventional studies under Stroke, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 18 months is below that.

Counting every sponsor, half of 132 studies reached it within 40 months; a quarter within 24 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 5, 2025
StartActual
Mar 18, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2029
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07104487
Responsible party
Sponsor
First posted
Aug 5, 2025
Start date
Mar 18, 2025
Primary completion
Sep 2026 (estimated)
Completion
Sep 2029 (estimated)
Last update
Aug 11, 2025

Study contacts

Robin Lemmens, MD PhD
Contact
robin.lemmens@uzleuven.be
+32 16 34 42 80
Louise Maes, MD
Contact
louise.maes@uzleuven.be
+32 16 34 42 80
Robin Lemmens, MD PhD
principal investigator · UZ Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion